Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma

Acta Pharmacologica Sinica

Volumn 31, Issue 9, 2010, Pages 1165-1171

  Chen, Leilei ^a   Chan, Tim Hon Man ^a   Guan, Xin Yuan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

1q21; amplification; CHD1L; hepatocellular carcinoma; oncogene

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IBETA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN;

AMPLICON; APOPTOSIS; BINDING AFFINITY; CANCER GROWTH; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMOSOME 13Q; CHROMOSOME 16P; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 4Q; CHROMOSOME 6Q; CHROMOSOME 8P; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DISTANT METASTASIS; DRUG INHIBITION; GENE AMPLIFICATION; GENE LOSS; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GENETIC GAIN; GENETIC TRANSFECTION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MINIMAL AMPLIFIED REGION; NONHUMAN; ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHROMOSOMES, HUMAN, PAIR 1; DNA HELICASES; DNA-BINDING PROTEINS; GENE AMPLIFICATION; HUMANS; ONCOGENES;

EID: 77956361953     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.94     Document Type: Review

References (60)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-8.
3. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38: S136-49.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
5. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v.
6. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-1133
7. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468
8. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127: S79-86.
9. Debernardi S, Lillington D, Young BD. Understanding cancer at the chromosome level: 40 years of progress. Eur J Cancer 2004; 40: 1960-1967
10. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994; 91: 822-826
11. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
12. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532
13. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997; 18: 59-65.
14. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999; 29: 1858-1862
15. Sakakura C, Hagiwara A, Taniguchi H, Yamaguchi T, Yamagishi H, Takahashi T, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer 1999; 80: 2034-2039
16. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154: 37-43.
17. Guan XY, Fang Y, Sham JS, Kwong DL, Zhang Y, Liang Q, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000; 29: 110-116
18. Chang J, Kim NG, Piao Z, Park C, Park KS, Paik YK, et al. Assessment of chromosomal losses and gains in hepatocellular carcinoma. Cancer Lett 2002; 182: 193-202.
19. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001; 85: 697-704.
20. Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, et al. A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 2001; 60: 151-161
21. Balsara BR, Pei J, De Rienzo A, Simon D, Tosolini A, Lu YY, et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 2001; 30: 245-253
22. Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H, et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004; 64: 7263-7270
23. Lau SH, Guan XY. Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin 2005; 26: 659-665
24. Poon TC, Wong N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006; 131: 1262-1270
25. Qin LX, Tang ZY, Sham JS, Ma ZC, Ye SL, Zhou XD, et al. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 1999; 59: 5662-5665
26. Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002; 95: 2346-2352
27. Nishimura T, Nishida N, Itoh T, Komeda T, Fukuda Y, Ikai I, et al. Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. Genes Chromosomes Cancer 2005; 42: 34-43.
28. Nishimura T, Nishida N, Itoh T, Kuno M, Minata M, Komeda T, et al. Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. Genes Chromosomes Cancer 2002; 35: 329-339
29. Gronwald J, Storkel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, et al. Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Cancer Res 1997; 57:481-487
30. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer 2000; 82: 65-73.
31. Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res 1999; 5: 2526-2531
32. Hirai M, Yoshida S, Kashiwagi H, Kawamura T, Ishikawa T, Kaneko M, et al. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment. Genes Chromosomes Cancer 1999; 25: 261-269
33. Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 2008; 47: 503-510
34. Vissers LE, Veltman JA, van Kessel AG, Brunner HG. Identification of disease genes by whole genome CGH arrays. Hum Mol Genet 2005; 14: R215-23.
35. Inagaki Y, Yasui K, Endo M, Nakajima T, Zen K, Tsuji K, et al. CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma. Cancer Genet Cytogenet 2008; 180: 30-36
36. Wong N, Chan A, Lee SW, Lam E, To KF, Lai PB, et al. Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol 2003; 38: 298-306.
37. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219
38. Lencioni R, Caramella D, Bartolozzi C, Di Coscio G. Long-term follow-up study of adenomatous hyperplasia in liver cirrhosis. Ital J Gastroenterol 1994; 26: 163-168
39. Theise ND, Park YN, Kojiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 2002; 6: 497-512.
40. Qi H, Fillion C, Labrie Y, Grenier J, Fournier A, Berger L, et al. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is upregulated by androgens in LNCaP human prostate cancer cells. Cancer Res 2002; 62: 721-733
41. Pan JS, Cai JY, Xie CX, Zhou F, Zhang ZP, Dong J, et al. Interacting with HBsAg compromises resistance of jumping translocation breakpoint protein to ultraviolet radiation-induced apoptosis in 293FT cells. Cancer Lett 2009; 285: 151-156
42. Kanome T, Itoh N, Ishikawa F, Mori K, Kim-Kaneyama JR, Nose K, et al. Characterization of Jumping translocation breakpoint (JTB) gene product isolated as a TGF-beta1-inducible clone involved in regulation of mitochondrial function, cell growth and cell death. Oncogene 2007; 26: 5991-6001.
43. Huebner K, Kastury K, Druck T, Salcini AE, Lanfrancone L, Pelicci G, et al. Chromosome locations of genes encoding human signal transduction adapter proteins, Nck (NCK), Shc (SHC1), and Grb2 (GRB2). Genomics 1994; 22: 281-287
44. Kraut-Cohen J, Muller WJ, Elson A. Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling. J Biol Chem 2008; 283: 4612-4621
45. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, et al. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 2007; 315: 659-663
46. Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR Jr. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res 2003; 63: 6772-6783
47. Wang XC, Tian J, Tian LL, Wu HL, Meng AM, Ma TH, et al. Role of Cks1 amplification and overexpression in breast cancer. Biochem Biophys Res Commun 2009; 379: 1107-1113
48. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M, et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001; 3: 321-324
49. Rother K, Li YY, Tschop K, Kirschner R, Muller GA, Mossner J, et al. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73. Cell Cycle 2007; 6: 853-862
50. Shen DY, Fang ZX, You P, Liu PG, Wang F, Huang CL, et al. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int 2009; 30: 119-125
51. Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009; 137: 1816-1826
52. Flaus A, Martin DM, Barton GJ, Owen-Hughes T. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res 2006; 34: 2887-2905
53. Karras GI, Kustatscher G, Buhecha HR, Allen MD, Pugieux C, Sait F, et al. The macro domain is an ADP-ribose binding module. EMBO J 2005; 24: 1911-1920
54. Ahel D, Horejsi Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 2009; 325: 1240-1243
55. Chen M, Huang JD, Hu L, Zheng BJ, Chen L, Tsang SL, et al. Transgenic CHD1L expression in mouse induces spontaneous tumors. PLoS One 2009; 4: e6727.
56. Chen L, Hu L, Chan TH, Tsao GS, Xie D, Huo KK, et al. Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. Hepatology 2009; 50: 122-129.
57. Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 2010; 120: 1178-1191
58. Ruder C, Reimer T, Delgado-Martinez I, Hermosilla R, Engelsberg A, Nehring R, et al. EBAG9 adds a new layer of control on large densecore vesicle exocytosis via interaction with Snapin. Mol Biol Cell 2005; 16: 1245-1257
59. Zhang F, Wu J, Yu X. Integrator3, a partner of single-stranded DNAbinding protein 1, participates in the DNA damage response. J Biol Chem 2009; 284: 30408-30415
60. Huang J, Gong Z, Ghosal G, Chen J. SOSS complexes participate in the maintenance of genomic stability. Mol Cell 2009; 35: 384-393